Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 64 Publications

13 Customer Reviews

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Cells were cultured with the indicated concentrations of PLS-123, rapamycin (Granta519 0.002 μM, Mino 0.001 μM, Z138 0.005 μM), and their combination for 48 h. The results are expressed as the mean of relative activity and S.D. from triplicate cultures. The results are representative of at least three similar experiments.

    Int J Cancer, 2018, 142(1):202-213. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

    Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

  • Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

    Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

  • Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

    2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 MV7DfZRwfG:6aXOgRZN{[Xl? MnfJNVAhdk1? M4HHd|czKGh? NYruTXpQTE2VTx?= NIm4XI5Rd3SnboTpZZRmeyClYX3weI91cGWlaX6tbY5lfWOnZDDjfZRwfG:6aXPpeJk> NYf0W3NZOjR7MEC4O|M>
HT-29 NXnpW41CS3m2b4TvfIlkKEG|c3H5 NYXnS202OTBibl2= Mo\FO|IhcA>? NFXV[ZBFVVOR MlG3VI91\W62aXH0[ZMh\GmpaYTvfIlvNWmwZIXj[YQh[3m2b4TvfIlkcXS7 M{K4U|I1QTByOEez
HT-29 MWDDfZRwfG:6aXOgRZN{[Xl? MXexNEBvVQ>? NWfs[VB1PzJiaB?= NXvlSXF2TE2VTx?= M17zW3BwfGWwdHnheIV{KDVvZnz1c5JwfXKjY3nsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 MlraNlQ6ODB6N{O=
PC3 NWn3V3duU2mwYYPlJGF{e2G7 NXj1eHl3OTByIH7N NYTjemM5OSCq NWrpd2ZHTE2VTx?= MmG4VI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFwyOCCwTT6= NX[3e5JuOjF7N{i2PFM>
PC3 MlrCT4lv[XOnIFHzd4F6 M2TmdFExOCCwTR?= MmPKNUBp MnXkSG1UVw>? MYrEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NVHyWZNpOjF7N{i2PFM>
PC3 NVfaW4dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HvTFEvPSEQvF2= M4rvPVEhcA>? Mk\aSG1UVw>? MkPWTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyC5aYToJGlEPTBib3[gQFExKG6P MYKyNVk4QDZ6Mx?=
HEK293 M2T2UWZ2dmO2aX;uJGF{e2G7 M1;UclExOCCwTR?= MkCyPEBp NEiyVItFVVOR MlzUTY5pcWKrdIOgWHBCNWmwZIXj[YQh\GWpcnHkZZRqd25ib3[gVIRk\DRid3n0bEBGSzVyIH;mJFUxKG6P MoH1NlE2Ozl|MEG=
BT-20 MVPLbY5ie2ViQYPzZZk> MnzENlAh|ryP M4XRdGROW09? M37vS2Rw\XNibn;0JIlvcGmkaYSgcXRQWkN{IHTldIVv\GWwdDDwRYtVKFN2N{OgdIhwe3Cqb4L5cIF1cW:w MW[yNVM2OzV3MR?=
U937 M{DiV2FvfGmkYXP0[ZJq[WxiQYPzZZk> MlLDOVAh|ryP NFXp[mY1QCCq M3TuO2ROW09? NGXocJdKdmS3Y3XzJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCC5aXzkJJR6eGViTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBRcGmuYXTlcJBpcWFvMTDKVlMzKGmwIGW5N|ch[2WubIO= NYjQSVJSOjFzNEKxNFY>
U937 NFTDd2xCdnSrYnHjeIVzcWGuIFHzd4F6 MXe1NEDPxE1? NXfZXpVzPDhiaB?= NFv4WJRFVVOR Mn76SI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBOUVBicILveIVqdi2mZX\pZ4lmdnRiTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBLWjN{LUKgbY4hXTl|NzDj[Yxtew>? NHPv[VIzOTF2MkGwOi=>
U937 M1XRdGFvfGmkYXP0[ZJq[WxiQYPzZZk> M13jZVUxKM7:TR?= NFHJV2k1QCCq M3vGPWROW09? M{TwfWRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhTXOlaHXybYNpcWFiY3;sbUBJSjFyMTDpckBWQTN5IHPlcIx{ M4DjfVIyOTR{MUC2
MCF-7 MYHBeZRweGijZ4mgRZN{[Xl? NWC2UG5ROzBibl2= NXW1SWxYPCCq MUfEUXNQ M1PU[Glv\HWlZYOgZZV1d3CqYXf5 NFjjVIYzODB{OEGzOC=>
U87MG NHf4XXRMcW6jc3WgRZN{[Xl? M1PRfFEh|ryP NXvRZ4JKPiCq MYLEUXNQ NUTzUoxIWG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36= NYrS[4Y6OTl6NEi0NFQ>
U87MG MmT1T4lv[XOnIFHzd4F6 MVOxJO69VQ>? MWG2JIg> MUjEUXNQ NX3r[|ByWG:2ZX70cJkhcW6qaXLpeJMhPEWEUEGoWFcxMSCyaH;zdIhwenmuYYTpc44> MWOxPVg1QDRyNB?=
U87MG NUXYXWJ1U2mwYYPlJGF{e2G7 M4LiV|Eh|ryP MUG2JIg> M1rGW2ROW09? NHW0THFFd2W|IH7veEBqdmirYnn0JI1VV1JvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?= NE\0eWgyQTh2OESwOC=>
U87MG NF3YSJlMcW6jc3WgRZN{[Xl? NVjJXJlrOSEQvF2= MmTlOkBp NVWyTVNITE2VTx?= MU\Ec4V{KG6xdDDpcohq[mm2IGCtOGVDWDFqVEO3M|Q3MSCyaH;zdIhwenmuYYTpc44> MVqxPVg1QDRyNB?=
COS7 cells expressing EGFP-HDQ74/rheb NEXFPJZCfXSxcHjh[5khSXO|YYm= NGrueYwxNjJizszN NGLQTpYzPCCq MmS2SG1UVw>? NVfPZnNmUW6mdXPld{BifXSxcHjh[5k> NGnmUGwyQDN7MUm0PS=>
COS7 cells expressing EGFP-LC3 M{Lwe2F2fG:yaHHnfUBCe3OjeR?= NX[2WGdjOC5{IN88US=> M2\vbVI1KGh? NWjsWZNVTE2VTx?= NFj5[JRKdmS3Y3XzJIF2fG:yaHHnfS=> MmnCNVg{QTF7NEm=
H4 NEizb2xHfW6ldHnvckBCe3OjeR?= NIC4NHQxNjJizszN NIjFdFUzPCCq Ml\WSG1UVw>? Mn;hTY5kemWjc3XzJJRp\SC{YYTpc{Bw\iCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNkB1dyCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNUBqdiCqdX3hckBJPCClZXzsdy=> MlrTNVgxOjR3OES=
HeLa NVX4NnF1TnWwY4Tpc44hSXO|YYm= MVKxNFAhdk1? M4Xmd|M3KGh? M2nvN2ROW09? Mm\GTY5lfWOnczDGVmIhUzJyOUXQMEBVOjB7OFysJHczOTBzRjDteZRidnRvdXLpdZVqfGmwQzDpcpRmemGldHnvci=> NVnaUZNmOTd3NkOzPFU>
HeLa NFXCVVRHfW6ldHnvckBCe3OjeR?= NGj5S2QyODBibl2= Ml;jN|YhcA>? NHzpZlZFVVOR NHPXdpBKdmS3Y3XzJGZTSiCZMkGwNWYhdXW2YX70MZVjcXG3aYTpcmMhcW62ZYLhZ5Rqd25? M{[2d|E4PTZ|M{i1
HeLa NHnm[3FHfW6ldHnvckBCe3OjeR?= MW[xNFAhdk1? MUOzOkBp MYPEUXNQ NF3vUldKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> NITVW5IyPzV4M{O4OS=>
SYF M4\KfGZ2dmO2aX;uJGF{e2G7 NHy5NJcyODBibl2= Mo\jNlQhcA>? NU\4UWdYTE2VTx?= NEn6Oo5KdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> NXzWeJFDOTd3NkOzPFU>
SYF MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DWUVExOCCwTR?= Ml;uNlQhcA>? M17hWmROW09? MY\JcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiU2nGJINmdGy| NIfOT2IyPzV4M{O4OS=>
HEK293T MkmzRY51cX[rcnHsJGF{e2G7 Mo[yNUBvVQ>? NXfHOoJoPCCm M3P2SWROW09? NGfMW5FKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiUkWge4l1cCCHQ{WwJI9nKDBwMTDuUS=> MkPFNVc1QDV3MEG=
HEK293T MXXBcpRqfmm{YXygRZN{[Xl? NF;uZ4MyKG6P NXjXdWNEPCCm NUD2VGk3TE2VTx?= NX\wclJOUW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGi0JJdqfGhiRVO1NEBw\iByLkOgcm0> NFrSepEyPzR6NUWwNS=>
PBMC MmnCSpVv[3Srb36gRZN{[Xl? MXuxJI5O NVTqd|VDOTRiZB?= Mlz5SG1UVw>? NYq5UY9MWmWmdXPld{BES1J3IHTlcpNqfHl? NX3mZ5B1OTd2OEW1NFE>
PBMC NWn6e4x5TnWwY4Tpc44hSXO|YYm= NID3TpkyKG6P M1;sOlE1KGR? NHLmcVFFVVOR NWHtO3ZPTG:nczDuc5Qh[W[oZXP0JGNZS1J2IHTlcpNqfHl? NX:3SYRoOTd2OEW1NFE>
HEK293 cells MXPLbY5ie2ViQYPzZZk> NEHMXWQ2OCCwTR?= NWHie4ZYPDVibXnu NE[xSVVFVVOR MXHJcohq[mm2czDtWG9TKGurbnHz[UBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xJI5O MmGyNVc{PTB7NUO=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MXnGeY5kfGmxbjDBd5NigQ>? MXuxNFAhdk1? MnfiOEBp M1zDemROW09? NV\sbFU4UW6mdXPld{BtfWOrZnXyZZNmKHC{b4TlbY4hfHKjboOtd5BtcWOrbnegbY4hTHKxc3;wbIlt[SCvZXzhco9o[XO2ZYKgV|Ih[2WubIOgeJJidnOoZXP0[YQhf2m2aDDOMYx2[yCjbnSgR{1tfWN? NXLhfJVsOTdzMkiyOlI>
Human mixed lymphocyte NGXwOYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVW4e5VIPSCwTR?= NWLtcoRLTE2VTx?= NUH2OoxtUUN3ME2xMlYhdk1w Mli0NVYyQDV6NkW=
Lewis rat lymph node cells M2e2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTnOUDPxE1? NUm3WHNTTE2VTx?= NWnoWWRSUUN3ME2yMlYh|ryP M37kclE3OTh3OE[1
cells from the thymus of normal BALB/c mice NIWx[XNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV71ZnNOOTBibl2= NGGxOXc4OiCq MWrEUXNQ MXzJcohq[mm2czDsfY1xcG:ycn;sbYZmemG2aX;uJEhNSUZrIIfpeIghUUN3MDDv[kA{KG6P MVKxNFAzOTl2OB?=
MRK-nu-1 M1q0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwOES1JJBO NVn0XlZUW0GQR1XS
OCUB-M NXuxSmZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmCyTWM2OD13LkK0JJBO MU\TRW5ITVJ?
SF539 NV;rZ3diT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTFzLk[gdG0> MYPTRW5ITVJ?
ES4 M4C2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jvZ2lEPTB;MkGuOUBxVQ>? MljIV2FPT0WU
RL95-2 M4\hNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{i2TGlEPTB;MUC3JJBO Mnv1V2FPT0WU
LC-2-ad M4j6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;aPYpKSzVyPUSyN{BxVQ>? NVfMcZJFW0GQR1XS
Daudi MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DwXGlEPTB;NEO0JJBO MWTTRW5ITVJ?
NTERA-S-cl-D1 NWm0ZZNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYKwR3JpUUN3ME20OFMheE1? NFrLbYlUSU6JRWK=
OS-RC-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zJeWlEPTB;NkWyJJBO NF7zfVBUSU6JRWK=
VA-ES-BJ NYSzdGJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonqTWM2OD15MkOgdG0> M2r3W3NCVkeHUh?=
GR-ST NF7pWI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnJO4ZKSzVyPUi0OkBxVQ>? MXzTRW5ITVJ?
SW872 Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHmPFBKSzVyPUi0OkBxVQ>? M3HoOXNCVkeHUh?=
NOS-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLhO45LUUN3ME24O|EheE1? M2\kVHNCVkeHUh?=
MC116 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTl6NTDwUS=> MYrTRW5ITVJ?
NCI-H1355 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkmzTWM2OD1zLkCxJI5O NUDhR2NXW0GQR1XS
RPMI-8226 M{\QVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPOT4lKSzVyPUGuNVkhdk1? NHP4THBUSU6JRWK=
TE-15 M1TWe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTFwM{[gcm0> MonDV2FPT0WU
Ramos-2G6-4C10 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPFSVhKSzVyPUGuOFYhdk1? Mm\PV2FPT0WU
KU812 MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\DTWM2OD1{LkCxJI5O NFrpfItUSU6JRWK=
EW-1 NYC2fW0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPk[3B[UUN3ME2yMlE4KG6P MlrBV2FPT0WU
KS-1 NFfNNnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXyOFNKSzVyPUKuOFUhdk1? NV3QfIRJW0GQR1XS
SK-LMS-1 Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXvTWM2OD1{LkS5JI5O MkPiV2FPT0WU
TGBC1TKB NEjyVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r1d2lEPTB;Mj62PUBvVQ>? MnPhV2FPT0WU
TE-6 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\ZfmlEPTB;Mj63O{BvVQ>? MorWV2FPT0WU
ETK-1 NFP3TI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITQN4dKSzVyPUKuPFIhdk1? NETXZ2lUSU6JRWK=
BE-13 NGnoS5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LSR2lEPTB;Mj65PUBvVQ>? NGGxSlZUSU6JRWK=
A3-KAW MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJwOUmgcm0> MlLtV2FPT0WU
TE-10 M3\R[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\0TWM2OD1|LkOgcm0> Mo\uV2FPT0WU
DOHH-2 MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnDTWM2OD1|LkO1JI5O MnrnV2FPT0WU
ES6 NF;qdXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jNbGlEPTB;Mz60N{BvVQ>? NYXUR3lMW0GQR1XS
OPM-2 Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\hTWM2OD12LkG1JI5O M2nQbXNCVkeHUh?=
SH-4 NVvKOGpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{W5WGlEPTB;ND6zOEBvVQ>? Mk\OV2FPT0WU
NB13 Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnO5TWM2OD12LkO2JI5O M3XPXnNCVkeHUh?=
HUTU-80 M2DEVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\qSZFoUUN3ME20MlQzKG6P MnHOV2FPT0WU
CCRF-CEM M3y5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTRwOUSgcm0> NHzSNJpUSU6JRWK=
TGBC24TKB MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\YTWM2OD13LkWxJI5O M33wZ3NCVkeHUh?=
697 M4flfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3NS|JKSzVyPU[uNlghdk1? NFi2UlNUSU6JRWK=
J-RT3-T3-5 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTZwNE[gcm0> NW\oN4FbW0GQR1XS
KALS-1 NHvCR4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXPUWlKSzVyPU[uOVYhdk1? M3jUeHNCVkeHUh?=
no-10 NHjG[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIi3eHhKSzVyPUeuNlkhdk1? M{ntOHNCVkeHUh?=
SK-NEP-1 NYLUdmdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\uTWM2OD16Lke5JI5O NVTyZWFsW0GQR1XS
L-540 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\ndGlEPTB;MUCuOFIhdk1? Mm\tV2FPT0WU
JiyoyeP-2003 Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILhOJhKSzVyPUGwMlk1KG6P MnzpV2FPT0WU
HH M1rqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HYUWlEPTB;MUGuN|khdk1? NV3RSI9SW0GQR1XS
SR NHj6XVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4q5TmlEPTB;MUGuOFUhdk1? NFS4WGxUSU6JRWK=
QIMR-WIL MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPse3hKSzVyPUGxMlg2KG6P NHfKW|JUSU6JRWK=
A4-Fuk MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv1TWM2OD1zMz6xNkBvVQ>? M3;OT3NCVkeHUh?=
CESS M1foZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\RO49KSzVyPUGzMlE{KG6P MlvwV2FPT0WU
KE-37 NWr1UmdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\qSXZKSzVyPUG2MlA4KG6P NYjtbFh1W0GQR1XS
SK-UT-1 NF;RW|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT5TWM2OD1zNj64NUBvVQ>? NFXWR4JUSU6JRWK=
SIG-M5 NHjkOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjjVJRKSzVyPUG3MlI2KG6P NUfDOHVUW0GQR1XS
HT NUfPfpdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF5Lk[gcm0> M1vVbHNCVkeHUh?=
DEL NHTtRndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvBTWM2OD1zNz65PUBvVQ>? NHjY[ohUSU6JRWK=
SK-PN-DW NYHFb3BHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHlTWM2OD1{MD6yN{BvVQ>? M13o[nNCVkeHUh?=
RPMI-8402 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zyWmlEPTB;MkGuO|chdk1? MUjTRW5ITVJ?
RPMI-6666 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJ2LkSyJI5O NUnXb|Y4W0GQR1XS
NCI-H720 MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTCTWM2OD1{NT60NUBvVQ>? MUjTRW5ITVJ?
EW-16 M1\Wdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLPTGdWUUN3ME2yOk45PyCwTR?= Mof5V2FPT0WU
BL-70 MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGflPHJKSzVyPUK4MlM5KG6P MUjTRW5ITVJ?
SF126 MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH3[GZFUUN3ME2zNE4{QCCwTR?= MmLyV2FPT0WU
BC-1 NHW2W5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K3RmlEPTB;M{GuNlYhdk1? MnXrV2FPT0WU
MHH-PREB-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2e3b2lEPTB;M{KuOFQhdk1? NEPVUZhUSU6JRWK=
A101D NYDofFQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTN{Lk[yJI5O NVzXbXo5W0GQR1XS
NMC-G1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\ob2hKSzVyPUOzMlY4KG6P MlfJV2FPT0WU
LB1047-RCC M1fGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnoOVZKSzVyPUO0MlY6KG6P M1jofnNCVkeHUh?=
EM-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHW0emhKSzVyPUO4MlU{KG6P Ml7iV2FPT0WU
COLO-684 M132WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDTTWM2OD1|OT64JI5O MVrTRW5ITVJ?
Becker NVH4WGRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nNb2lEPTB;NEGuNFUhdk1? NHvjc3JUSU6JRWK=
BL-41 MnjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTR|Lk[2JI5O NF7lVoVUSU6JRWK=
MDA-MB-134-VI MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rnVWlEPTB;NESuNFIhdk1? NXLIcVJvW0GQR1XS
L-363 NHrlPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HjWWlEPTB;NESuO|Mhdk1? MkC1V2FPT0WU
ECC4 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\IRZhGUUN3ME20OE44QCCwTR?= NWDZZYNOW0GQR1XS
A388 NELufJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHROIZKSzVyPUS0MlgzKG6P NFPvR4ZUSU6JRWK=
HEL NF;FZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTsNolkUUN3ME20PU44QSCwTR?= M3zKcnNCVkeHUh?=
RKO NWDuZnl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTVyLkK5JI5O NIHTSINUSU6JRWK=
KINGS-1 NGXoOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n2b2lEPTB;NUGuOVUhdk1? Mny5V2FPT0WU
EB-3 Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDHPIJKSzVyPUWyMlY4KG6P NVzTXnp7W0GQR1XS
ARH-77 NF\mS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTV{Lkigcm0> MWTTRW5ITVJ?
GCIY MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfLTHdlUUN3ME21N{41PiCwTR?= M1jGXHNCVkeHUh?=
NCI-H1304 M4\2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXPcoJrUUN3ME21O{4zOiCwTR?= NUfCU3YzW0GQR1XS
KARPAS-299 M13Ndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYqwNIttUUN3ME22NU45OiCwTR?= NFq1[WJUSU6JRWK=
IA-LM NH7LW|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT3eoRDUUN3ME22PE4yOyCwTR?= NVzPV4JwW0GQR1XS
GI-1 NEfYXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrS[mMzUUN3ME23NE4{QSCwTR?= M17nbnNCVkeHUh?=
TE-11 M{Dtdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDhOnVKSzVyPUe3MlE4KG6P NEP1dlZUSU6JRWK=
LS-411N MlPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTd5LkW3JI5O NF3iSnVUSU6JRWK=
no-11 NYTSU5g6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEf6clJKSzVyPUizMlI1KG6P MX7TRW5ITVJ?
MV-4-11 NV;4NmdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fySGlEPTB;OEOuO|Mhdk1? Mn;mV2FPT0WU
BV-173 MmLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu0TJhKSzVyPUizMlk4KG6P NYT2Z2JPW0GQR1XS
CMK NYfqZlY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jlNGlEPTB;OESuNVYhdk1? NXi2NlBwW0GQR1XS
LC4-1 NHzzOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPIcJZKSzVyPUi2MlczKG6P NUHKNWdbW0GQR1XS
COR-L279 NH6wb3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHMdpNKSzVyPUi3MlI2KG6P MmjqV2FPT0WU
NCI-H209 NWLqSXU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEe0eJNKSzVyPUi3MlQyKG6P MW\TRW5ITVJ?
Raji M2PpO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2f0dGlEPTB;OEmuO|Ihdk1? NFrMXoZUSU6JRWK=
LB996-RCC NEjFXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{S3U2lEPTB;OUOuOFMhdk1? M3roOXNCVkeHUh?=
NCI-H526 MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1e0U2lEPTB;OUOuOVkhdk1? NGfWOo9USU6JRWK=
KGN NULySGx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTl4LkK5JI5O NUThe3B3W0GQR1XS
MOLT-4 NYe5eppGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPJTWM2OD17Nj63PUBvVQ>? NWPJZ3hiW0GQR1XS
PF-382 Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;4foJYUUN3ME25Ok44QSCwTR?= M4nzPHNCVkeHUh?=
BC-3 NFTsRmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPPTWM2OD17OT6xPEBvVQ>? M13yPXNCVkeHUh?=
KARPAS-422 NUPIO2xLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HvXGlEPTB;MUCyMlA6KG6P Mkm4V2FPT0WU
SBC-1 M2eyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHyTWM2OD1zMEeuO|Uhdk1? MknhV2FPT0WU
LC-1F NVqydpZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f5fmlEPTB;MUC4MlA2KG6P NF3OOWVUSU6JRWK=
GB-1 M4fBeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDLbmlKSzVyPUGwPU4xOiCwTR?= NUmxWGwyW0GQR1XS
SNB75 M2\sVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljETWM2OD1zMUmuOlkhdk1? M3:4UXNCVkeHUh?=
BB65-RCC M4fEXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TwN2lEPTB;MUG5Mlk{KG6P NHXtNnNUSU6JRWK=
NCI-N87 NUja[oZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVP6[nM6UUN3ME2xNlEvQThibl2= NH7Ze2tUSU6JRWK=
IST-MEL1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYC2OYx2UUN3ME2xNlIvOzhibl2= Mnj6V2FPT0WU
HOP-62 NV3sW2s{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfWOIE5UUN3ME2xNlYvQDlibl2= MVjTRW5ITVJ?
ACN M1TOO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLCTWM2OD1zNE[uO|Uhdk1? NEjifFRUSU6JRWK=
DMS-114 MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlu4TWM2OD1zNUCuOlchdk1? M2\NWnNCVkeHUh?=
MLMA MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLLXIhHUUN3ME2xOVkvQDhibl2= NXvQOnBDW0GQR1XS
HT-144 M2jhRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF4NT60N{BvVQ>? MnLuV2FPT0WU
C2BBe1 NHLEVnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXlXYlKSzVyPUG2O{44PiCwTR?= MWrTRW5ITVJ?
L-428 NWHpcZJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ftU2lEPTB;MUe3Mlchdk1? NWLBe4I1W0GQR1XS
DU-4475 MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmP2TWM2OD1zOEeuOlghdk1? Ml24V2FPT0WU
CP67-MEL M{DWTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfhUmQ5UUN3ME2xPVkvOzhibl2= NHG1c4FUSU6JRWK=
MEG-01 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPnW3ZKSzVyPUKwNU46PiCwTR?= M33xdXNCVkeHUh?=
IST-SL2 NVrkfWdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXBTWM2OD1{MEiuOlMhdk1? NXTVTJVbW0GQR1XS
ES8 M4nKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnRS3lKSzVyPUKyOU46PCCwTR?= M1XVdnNCVkeHUh?=
COLO-800 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvHdXZKSzVyPUKzOU4zQCCwTR?= MYfTRW5ITVJ?
MFH-ino NX;qfI1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJ|NT64OEBvVQ>? MkfhV2FPT0WU
OVCAR-4 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjYdZVKSzVyPUKzO{4zPCCwTR?= MlP5V2FPT0WU
PSN1 NHj6WpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTJ2Mj63NUBvVQ>? NGG1UHpUSU6JRWK=
EW-12 MoXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD3TWM2OD1{NEOuNUBvVQ>? MmC1V2FPT0WU
HCC1599 M3nmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;hcJVKSzVyPUK2NU41PyCwTR?= NGnIbnJUSU6JRWK=
SJSA-1 M{LrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLXTWM2OD1{N{GuOFYhdk1? M4XDNXNCVkeHUh?=
ST486 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\WXmlEPTB;Mkm2MlE1KG6P MnTkV2FPT0WU
NOMO-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm4THlKSzVyPUOwNE4zOSCwTR?= Mn\SV2FPT0WU
MN-60 MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTNyNT6zNkBvVQ>? NET6SmhUSU6JRWK=
HCC1187 MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jSWWlEPTB;M{C3MlI2KG6P NEjrPIRUSU6JRWK=
SW982 NG\wVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1i5XmlEPTB;M{G0Mlc2KG6P NVf2coxsW0GQR1XS
LB647-SCLC NH7oc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjaTWM2OD1|MkiuO|Ehdk1? NWnQSXVMW0GQR1XS
HC-1 M2KybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTN|NT61JI5O NWDFSVc1W0GQR1XS
EHEB NUnsbGFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGT3ZnBKSzVyPUOzO{42OiCwTR?= NGjXXWlUSU6JRWK=
TUR MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH0UINRUUN3ME2zOlMvQTVibl2= MX7TRW5ITVJ?
LU-139 MlLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTN5OD6wNkBvVQ>? NX7KWHU1W0GQR1XS
NB1 NUfpenhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvXTWM2OD1|OESuOFUhdk1? NH3WcIlUSU6JRWK=
BB30-HNC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTN6OD6zNkBvVQ>? M3z2c3NCVkeHUh?=
HAL-01 MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3sTWM2OD1|OEmuNlYhdk1? NV;zcodGW0GQR1XS
K5 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjUTWM2OD12MUGuN|chdk1? MnTXV2FPT0WU
MZ2-MEL NYOzXYZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTRzMz62OEBvVQ>? NYPoVmtmW0GQR1XS
RXF393 NFLwNI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTRzNj60OUBvVQ>? MVnTRW5ITVJ?
NCI-H1648 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTRzNz61N{BvVQ>? NHfG[5dUSU6JRWK=
TE-12 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\XTWM2OD12M{SuNlYhdk1? M3z5ZnNCVkeHUh?=
EoL-1- NIG2e4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLRTWM2OD12M{euPVghdk1? MWjTRW5ITVJ?
JAR NWq1dIZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTR|OD62NkBvVQ>? M2nBUnNCVkeHUh?=
DSH1 NUjsSY1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjqTWM2OD12NUiuPVEhdk1? M1P6WnNCVkeHUh?=
NCI-H187 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3oTWM2OD12NkKuPFEhdk1? NIDFZnRUSU6JRWK=
HCE-4 MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTR5Nz62OkBvVQ>? NIG0UI1USU6JRWK=
8-MG-BA MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13pSGlEPTB;NUixMlUzKG6P NEXyTYNUSU6JRWK=
KLE M{Sz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvQNY93UUN3ME21PFUvOiCwTR?= NIrzPJBUSU6JRWK=
KNS-42 MkTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTV6Nj64NUBvVQ>? M1m0OnNCVkeHUh?=
MSTO-211H M{e2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTZyOT63OEBvVQ>? NHfBWZdUSU6JRWK=
GDM-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnJe|ZKSzVyPU[xOE4xQSCwTR?= MoPoV2FPT0WU
TE-1 M2jBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGGzdVRKSzVyPU[0Ok4yOiCwTR?= M17CVnNCVkeHUh?=
BT-474 M1zpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPzTWM2OD14NEeuNFYhdk1? NH7JbZFUSU6JRWK=
KARPAS-45 NVTFUpFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTZ2Nz62JI5O MUTTRW5ITVJ?
MOLT-16 NF;uV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTZ2Nz65N{BvVQ>? MmPXV2FPT0WU
KURAMOCHI MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTYTWM2OD14NUeuOVEhdk1? MlntV2FPT0WU
K-562 Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXhTWM2OD14NkmuOVEhdk1? NWnNSG1mW0GQR1XS
EKVX MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHnTWM2OD14N{KuO|Ehdk1? NWPjNlBbW0GQR1XS
GAK NH3xd5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTZ5NT6zJI5O NE\yco1USU6JRWK=
NCI-SNU-5 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nWRWlEPTB;NkmwMlAyKG6P NGLoT4JUSU6JRWK=
NCI-H2126 M2P4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rhNmlEPTB;N{K2Mlg4KG6P NXjiZXhRW0GQR1XS
CTV-1 NFTYVpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvjb4ZKSzVyPUe0OE46KG6P M3HzWnNCVkeHUh?=
SW962 MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf4TWM2OD15NEiuOFQhdk1? M{HwcnNCVkeHUh?=
MONO-MAC-6 M2\hXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPxUlExUUN3ME23OVYvQTNibl2= MnnFV2FPT0WU
NCI-H748 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHHNWNxUUN3ME23OVgvQTlibl2= MorQV2FPT0WU
NCI-H524 MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zLfmlEPTB;N{iwMlc{KG6P MmfZV2FPT0WU
LS-123 NHXaVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTd7NT62PUBvVQ>? MnrlV2FPT0WU
NB7 NEW0R2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjOZ5hUUUN3ME24NVQvOTRibl2= NYrSVnNsW0GQR1XS
LS-1034 M33ue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljqTWM2OD16MkiuPVghdk1? MlfjV2FPT0WU
TE-5 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfFXIt5UUN3ME24PFMvPTZibl2= NGi0ZXZUSU6JRWK=
A704 NX:wSmc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDNTWM2OD16OUmuNVUhdk1? M4XxWnNCVkeHUh?=
TK10 NHrBd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTlzNj6wN{BvVQ>? M1K4THNCVkeHUh?=
NCI-H345 M2fVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPXUmpKSzVyPUm0N{4zOiCwTR?= MY\TRW5ITVJ?
CGTH-W-1 NVi2dnExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1juSGlEPTB;OUS4MlE{KG6P NIjueVVUSU6JRWK=
NCI-H510A NGeydYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDjSoJTUUN3ME25PFUvOTJibl2= NYCyVJZMW0GQR1XS
NCI-H1963 MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\qNWlEPTB;MT6wN|I6OiEQvF2= NVT1VnJQW0GQR1XS
SCC-3 NHHqR29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[zTZdKSzVyPUGuNFM1OTRizszN NV71NYRTW0GQR1XS
EW-11 M1;FSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHsfXNyUUN3ME2xMlA5PzR|IN88US=> MnvCV2FPT0WU
CPC-N NHvPOXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4T2T2lEPTB;MT6wPFgh|ryP MnrlV2FPT0WU
NCI-H1417 M2L2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXKZWJKSzVyPUGuNVIzPiEQvF2= NEH2clVUSU6JRWK=
DG-75 M3n4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTFwMU[yPFUh|ryP Ml7sV2FPT0WU
HD-MY-Z M1XoV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTFwMU[0NVYh|ryP NVSySYhyW0GQR1XS
ATN-1 NYOxfYVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGO1Sm1KSzVyPUGuNlYzODlizszN NHjEVFFUSU6JRWK=
KM-H2 NEXHNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEGzW4RKSzVyPUGuNlY1ODhizszN NYTmXWt{W0GQR1XS
NCI-H2081 MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPDTWM2OD1zLkK2OlM4KM7:TR?= MVTTRW5ITVJ?
HL-60 NG\KdHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHFW|NKSzVyPUGuNlY6PTlizszN NGHNSI5USU6JRWK=
DB MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnuTWM2OD1zLkK3NlQzKM7:TR?= MWnTRW5ITVJ?
NCI-H1522 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFwMki4PFch|ryP NEm3WIFUSU6JRWK=
AM-38 NUXyOlZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml60TWM2OD1zLkOwO|Ih|ryP MWPTRW5ITVJ?
NCI-H446 NF;vcG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\PTWM2OD1zLkOyNVIyKM7:TR?= MUTTRW5ITVJ?
SU-DHL-1 MoPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFuzS|JKSzVyPUGuN|I5ODFizszN NH20N4FUSU6JRWK=
NH-12 MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHW1U|dKSzVyPUGuN|Y{PzRizszN MUnTRW5ITVJ?
DMS-79 NHzKUFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPONJBsUUN3ME2xMlM3QDZ4IN88US=> Mk\OV2FPT0WU
NCI-H716 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3P0cGlEPTB;MT6zPFk5PiEQvF2= M1\BbHNCVkeHUh?=
ML-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrUe5hKSzVyPUGuOFE2OjlizszN M1rB[nNCVkeHUh?=
NB10 NE[3OpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnSTWM2OD1zLkS2OlMzKM7:TR?= M4nKVnNCVkeHUh?=
ONS-76 NE\pXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTyTWM2OD1zLkWzOVY6KM7:TR?= MkTLV2FPT0WU
LOUCY MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnFTWM2OD1zLkW0OlU4KM7:TR?= NWrkOpJkW0GQR1XS
SCLC-21H MoTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\XfGlEPTB;MT61PFU5OiEQvF2= Mn3zV2FPT0WU
TGW NWnjNGxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37UbWlEPTB;MT62N|k4PSEQvF2= NVqz[5N4W0GQR1XS
LXF-289 NEnKZm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rv[GlEPTB;MT63N|I3QCEQvF2= M4PheXNCVkeHUh?=
BB49-HNC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Tod2lEPTB;MT63N|U5PiEQvF2= MVnTRW5ITVJ?
NCI-H747 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3hVnNLUUN3ME2xMlc2OzR4IN88US=> Mlq5V2FPT0WU
LU-165 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[1TWM2OD1zLki0PVg3KM7:TR?= MX3TRW5ITVJ?
OMC-1 M3rqdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3nS4JKSzVyPUGuPVUxPjZizszN MV;TRW5ITVJ?
RCC10RGB MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTFwOUW4NVch|ryP NUPuUJB2W0GQR1XS
SW684 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLldJpKSzVyPUGuPVYxQTlizszN NXi5NmF[W0GQR1XS
TE-8 NWPTeW5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi0[WlKSzVyPUKuNFU2PTlizszN NYHqcGpCW0GQR1XS
SK-N-DZ NWC5TJVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PBNmlEPTB;Mj6xN|I4PCEQvF2= NXvpOo5zW0GQR1XS
EVSA-T MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJwMUezNVUh|ryP NEXjNXVUSU6JRWK=
KASUMI-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vITGlEPTB;Mj6xPFgyPSEQvF2= MVLTRW5ITVJ?
NKM-1 M1\ud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHSTWM2OD1{LkK1OFczKM7:TR?= NVXZWIgxW0GQR1XS
CAL-148 NH7qZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJwM{O2NVQh|ryP MXjTRW5ITVJ?
NCI-H64 M1;4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTJwM{SyN|Ih|ryP NGSxZplUSU6JRWK=
KNS-81-FD NVrBRXpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:wXZVWUUN3ME2yMlM3PjJizszN NUW2OVdoW0GQR1XS
KM12 NELvSodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHBe|BKSzVyPUKuOFA5OzlizszN NYq2cnJvW0GQR1XS
SW954 NF7QOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJwNEe3O|kh|ryP NFjWdlZUSU6JRWK=
NCI-H1395 NITFbFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPOO4JKSzVyPUKuOVI3PDVizszN NUiwRXdrW0GQR1XS
DJM-1 NEfqc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJwNkC2N{DPxE1? Ml3SV2FPT0WU
COLO-668 NES1bZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2ThR2lEPTB;Mj64NlY6PSEQvF2= M3W4NXNCVkeHUh?=
NCI-H1436 MlzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\lRVdlUUN3ME2yMlg2PjF3IN88US=> NWjvSGM6W0GQR1XS
LB2241-RCC NWH3OGpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2i5PGlEPTB;Mj64Olg{QSEQvF2= M1jWNHNCVkeHUh?=
GT3TKB NXrUXod2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzzNIVKSzVyPUKuPFkxPTVizszN NWHCbGo3W0GQR1XS
COLO-824 M4nweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITBeYNKSzVyPUKuPFk4PjhizszN MVTTRW5ITVJ?
ES1 NGPLeHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPEeGF4UUN3ME2yMlg6QDd7IN88US=> MkXRV2FPT0WU
LB771-HNC NXjhS4ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3jfIdKSzVyPUKuPVA6PDZizszN MUfTRW5ITVJ?
GI-ME-N NG\nXZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnflTWM2OD1|LkCwPVA1KM7:TR?= MWTTRW5ITVJ?
NALM-6 NGnZSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzBd3BKSzVyPUOuNFA6OzNizszN NYTGfWh[W0GQR1XS
LU-134-A NGPROWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHT6NIdKSzVyPUOuNFU1OjVizszN MYjTRW5ITVJ?
DMS-153 Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2THeGlEPTB;Mz6wOVgzPCEQvF2= NF;pXZhUSU6JRWK=
MZ1-PC MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTNwMEmwO|gh|ryP NVnPbGI1W0GQR1XS
NCI-H1155 MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HNZ2lEPTB;Mz6xNVYyKM7:TR?= NUXhNnhQW0GQR1XS
CAS-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vObWlEPTB;Mz6xN|cxPyEQvF2= M1;FWnNCVkeHUh?=
D-502MG MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfuO4JKSzVyPUOuNVQ{QSEQvF2= NYnXNYVqW0GQR1XS
NCI-H2141 NEDqSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTNwMUe0OVIh|ryP MnLoV2FPT0WU
NB6 NITwOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTNwMUiyOVkh|ryP NGDwR|RUSU6JRWK=
NCCIT MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv4TWM2OD1|LkKxPFA6KM7:TR?= Ml[3V2FPT0WU
NB69 M4ryOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjQb5JKSzVyPUOuN|E5QTFizszN NW\1TJd2W0GQR1XS
JVM-2 M1\VRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTNwM{[0N|Mh|ryP NYjtcJhWW0GQR1XS
K052 M2rEemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGSyOmpKSzVyPUOuN|c6PjhizszN NHvWWWtUSU6JRWK=
HCC2157 M1Hxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTNwNUOyNlgh|ryP M2DL[XNCVkeHUh?=
KMOE-2 NGrFOpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTNwNUSyOFIh|ryP M16wXHNCVkeHUh?=
SF268 MkiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTNwN{G1OVQh|ryP MV;TRW5ITVJ?
CHP-126 NXTkPFI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXDTWM2OD1|Lke2OFU5KM7:TR?= NWX3SpRGW0GQR1XS
CP66-MEL Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUThbWdYUUN3ME2zMlc6ODl2IN88US=> NIjucVdUSU6JRWK=
NCI-H69 NGLwZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTRwMEG5N|Yh|ryP MX\TRW5ITVJ?
A253 NHPIcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLmTWM2OD12LkCyNVAyKM7:TR?= MlzrV2FPT0WU
NB14 NHOz[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDZd3pKSzVyPUSuNVA1PzlizszN Mnu1V2FPT0WU
NCI-H1694 NWXqUWVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYL0RnBmUUN3ME20MlE{OTF{IN88US=> M3nkVHNCVkeHUh?=
NCI-H2196 Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnKTWM2OD12LkG3NVY6KM7:TR?= NIDJWnVUSU6JRWK=
TE-9 MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLkRpB6UUN3ME20MlE4PTh{IN88US=> NVPVWGZ{W0GQR1XS
D-283MED M1XVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTRwMUi4OEDPxE1? MnL4V2FPT0WU
OCI-AML2 NYnYV21GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTRwMUm0PFkh|ryP NHzPRYpUSU6JRWK=
D-263MG MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPwWIVKSzVyPUSuNlI6PjFizszN NImyNJVUSU6JRWK=
MPP-89 MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTRwMkezNFQh|ryP NFLrbHJUSU6JRWK=
LAMA-84 MoL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTRwM{C0NlEh|ryP NYDKcJhPW0GQR1XS
LB373-MEL-D M{O1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnmTWM2OD12LkO2O|g6KM7:TR?= NHzl[4ZUSU6JRWK=
UACC-257 Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDyOI1TUUN3ME20MlM6PTN2IN88US=> NVTUcoViW0GQR1XS
MC-CAR MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTRwNEO5PUDPxE1? NHHxdWZUSU6JRWK=
COLO-320-HSR NF;CVZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLMelg{UUN3ME20MlQ1PDJ5IN88US=> M2H2WXNCVkeHUh?=
P30-OHK MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjEfGt7UUN3ME20MlY3PThzIN88US=> Mn;KV2FPT0WU
UACC-812 NUCw[lgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzM[GwyUUN3ME20MlY6OTZzIN88US=> NX;GdG5iW0GQR1XS
CTB-1 NWCwU45nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrveIVKSzVyPUSuO|E2PTVizszN MXnTRW5ITVJ?
ALL-PO MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTRwOESwO|ch|ryP NUnMN25NW0GQR1XS
SK-MEL-2 NETOV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\xclQxUUN3ME20Mlg3QTV3IN88US=> MWPTRW5ITVJ?
TC-YIK NUXHdVhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTRwOUe5OFIh|ryP NGPRUpRUSU6JRWK=
NCI-H1882 M2XDb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLIPXNjUUN3ME21MlAzODBzIN88US=> M1LIXHNCVkeHUh?=
MHH-CALL-2 NGfjOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnPboRwUUN3ME21MlA2ODR{IN88US=> M{C5WHNCVkeHUh?=
U-87-MG MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3yyVGlEPTB;NT6wPVQ3PiEQvF2= NV63XZJsW0GQR1XS
NCI-H1092 MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnPZXI4UUN3ME21MlI3PTV3IN88US=> MYTTRW5ITVJ?
TE-441-T MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTVwMke4NkDPxE1? NH7Nb5hUSU6JRWK=
SK-MEL-1 NYiyPWo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvD[pNKSzVyPUWuNlkxPDRizszN MULTRW5ITVJ?
EW-22 MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTVwMkm0OlYh|ryP NIO1WnFUSU6JRWK=
MZ7-mel Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\JTWM2OD13LkSwOlkyKM7:TR?= MVfTRW5ITVJ?
LP-1 NUjJNIxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlezTWM2OD13LkSxNlkyKM7:TR?= M3jne3NCVkeHUh?=
NCI-SNU-16 NXrNOpRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPjT3BWUUN3ME21MlY1ODd2IN88US=> NV:we|hjW0GQR1XS
LU-65 M1PWSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkm2TWM2OD13Lke2N|c{KM7:TR?= MlvpV2FPT0WU
CW-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTVwOEW5OVkh|ryP MnvhV2FPT0WU
WSU-NHL NXLx[FY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnGTWM2OD13Lkm1NVc1KM7:TR?= NFrGfHFUSU6JRWK=
IST-MES1 NUTreWhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr1No1KSzVyPUWuPVU1PDNizszN MWfTRW5ITVJ?
U-266 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTVwOUiyNFIh|ryP M1rQdnNCVkeHUh?=
TALL-1 MoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXu1[IRuUUN3ME22MlE1Pjh6IN88US=> M3jrXHNCVkeHUh?=
Calu-6 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvrT2dYUUN3ME22MlE2OzF4IN88US=> NY\l[JZ6W0GQR1XS
MMAC-SF MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnITXVKSzVyPU[uNVg2PTZizszN MlPmV2FPT0WU
NCI-H82 M3mzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTZwMkC0PFkh|ryP MVnTRW5ITVJ?
RS4-11 Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Owe2lEPTB;Nj6yOVg6PyEQvF2= NYfNTWtZW0GQR1XS
SNU-C2B MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXQZ5ZKSzVyPU[uOFA6PjlizszN MoDFV2FPT0WU
BOKU NGH0THRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;JN5hZUUN3ME22MlQ4PTl5IN88US=> NYXNSppkW0GQR1XS
C8166 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu5OpRHUUN3ME22MlU2QTF{IN88US=> MnfUV2FPT0WU
D-247MG MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTdwMESzOFch|ryP NIrMXnRUSU6JRWK=
EW-18 MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Lpc2lEPTB;Nz6wO|I6OiEQvF2= NXTyZld6W0GQR1XS
KG-1 M3z3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTdwNkK3N|gh|ryP NWO4OJNRW0GQR1XS
REH M3r4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4iyZ2lEPTB;Nz62PFExQSEQvF2= Mmr5V2FPT0WU
U-698-M NIPUd4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\XWmJKSzVyPUeuPFQ{OTVizszN MoXGV2FPT0WU
KP-N-RT-BM-1 MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PuTWlEPTB;Nz65N|AzQSEQvF2= NXXaSZAxW0GQR1XS
MS-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7rTWM2OD15Lkm2NFQyKM7:TR?= M123RXNCVkeHUh?=
SNU-C1 NYX6bYN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHDTWM2OD15Lkm4NVkzKM7:TR?= M374UXNCVkeHUh?=
SK-MM-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[5TWM2OD16LkK2NFY2KM7:TR?= NUPZNJBtW0GQR1XS
LAN-6 MmDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HLXGlEPTB;OD6zNFAxOSEQvF2= NUjvXmdpW0GQR1XS
NEC8 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\WSo5KSzVyPUiuN|A3QTFizszN M2nlV3NCVkeHUh?=
NCI-H1770 MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\oc4M2UUN3ME24MlM5ODB{IN88US=> NFjVSmNUSU6JRWK=
D-336MG M4ftbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPpTWM2OD16LkSwNVE3KM7:TR?= M13y[HNCVkeHUh?=
COLO-829 M17PRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfIOYdKSzVyPUiuOFg5PzlizszN M{LQcnNCVkeHUh?=
LS-513 NYrrOJE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIi2bnlKSzVyPUiuOVk2QTlizszN MV\TRW5ITVJ?
YT NULHVWduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnzcmxPUUN3ME24MlYzPDJ5IN88US=> MoHtV2FPT0WU
EW-24 MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q3V2lEPTB;OD63OlU1KM7:TR?= MULTRW5ITVJ?
IST-SL1 M1Ll[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DlU2lEPTB;OD64OlU1OyEQvF2= MYrTRW5ITVJ?
CA46 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnq0TWM2OD16Lkm1NFk5KM7:TR?= NWrR[Yg4W0GQR1XS
NCI-H1838 NXX3V5Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\LNJRbUUN3ME24Mlk5PjB{IN88US=> MWTTRW5ITVJ?
NCI-H719 M1X5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTlwMkWyO|kh|ryP MXvTRW5ITVJ?
HCE-T NGnm[5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mki5TWM2OD17LkOwPFUyKM7:TR?= NV7XfIZHW0GQR1XS
A498 NW\rRYkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4CzOWlEPTB;OT6zOlEzPCEQvF2= MkX5V2FPT0WU
LB831-BLC NHXKfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\aXWtKSzVyPUmuO|Y2OjFizszN M1q4OHNCVkeHUh?=
SKM-1 NFXp[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP2NIlKSzVyPUmuPFU6PjNizszN NGm4WINUSU6JRWK=
THP-1 MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[wTWM2OD17Lkm2PVE5KM7:TR?= MnzEV2FPT0WU
SHP-77 M1TMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHJ[2dKSzVyPUGwMlQxPyEQvF2= M{jQfnNCVkeHUh?=
EW-3 M2fu[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3npfmlEPTB;MUCuOlI5QSEQvF2= Mn3vV2FPT0WU
KY821 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\3cW5IUUN3ME2xNE44PjNizszN M33hR3NCVkeHUh?=
NCI-SNU-1 NWnGcIhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTFzLkCyNVch|ryP MXHTRW5ITVJ?
HCC2218 NX21V|R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq4OY9iUUN3ME2xNU4{QTh4IN88US=> NI\RWlFUSU6JRWK=
IM-9 M{Liemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3LTWM2OD1zMT61NVA3KM7:TR?= NWT3W4dwW0GQR1XS
NCI-H889 M1HhZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\PSlZjUUN3ME2xNU42OzF|IN88US=> MojvV2FPT0WU
HDLM-2 MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PNbWlEPTB;MUKuOFE2QSEQvF2= MnPOV2FPT0WU
LB2518-MEL NH\5PWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe0PXdNUUN3ME2xNk43QDF3IN88US=> NILFfGRUSU6JRWK=
NCI-H23 MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULUbGhqUUN3ME2xN{4zPDJ3IN88US=> NWL4NmdpW0GQR1XS
NB17 NEfXVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3qWpJ6UUN3ME2xN{41PTd7IN88US=> NHHaemxUSU6JRWK=
NCI-H322M M1X0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fmcGlEPTB;MUSuOFA3QCEQvF2= Mn3JV2FPT0WU
SUP-T1 M3POUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDUO3puUUN3ME2xOE41OTNizszN Mnu3V2FPT0WU
ES3 M{Wxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO0cZpYUUN3ME2xOU4xPzB|IN88US=> M{XOPXNCVkeHUh?=
ES5 M{TVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;2SGlEPTB;MUWuNFc5PyEQvF2= NUPlPYVlW0GQR1XS
NCI-H1650 NU\xeFNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTqcYtKSzVyPUG1MlQ6PzlizszN MlvJV2FPT0WU
NCI-H226 MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTF3Lki3Olgh|ryP NY\rO|ZMW0GQR1XS
COR-L88 NHPKb|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXoTWM2OD1zNj6zNVQh|ryP NHnTfXVUSU6JRWK=
SCC-15 NV3qVXJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTF4LkO4Olkh|ryP NGK0O|FUSU6JRWK=
GOTO M2TBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[0TWM2OD1zNj60O|k{KM7:TR?= NXr4cm9ZW0GQR1XS
SIMA MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPtTWM2OD1zNj60PFAzKM7:TR?= NVLYSY5tW0GQR1XS
NCI-H1299 NWXCSW1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP5U5h4UUN3ME2xO{4yPTlzIN88US=> MnrOV2FPT0WU
NCI-H1581 NF3jNIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF5LkSyNVkh|ryP NH:wXVNUSU6JRWK=
MHH-NB-11 M4q0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{S4eGlEPTB;MUeuPVY5OyEQvF2= M4LHXHNCVkeHUh?=
MFM-223 NWGyXlhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTpcHdIUUN3ME2xPE4xPTN6IN88US=> MlHzV2FPT0WU
ES7 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzHPVZKUUN3ME2xPE42PDNzIN88US=> MlzoV2FPT0WU
JVM-3 NFy4OVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e4eWlEPTB;MUiuO|E4KM7:TR?= Ml76V2FPT0WU
RL NYjzTphjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\1TWM2OD1{MD6zPFgh|ryP M{ntXnNCVkeHUh?=
EC-GI-10 M4fId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJzLkKwOFEh|ryP NF:4Z4VUSU6JRWK=
LNCaP-Clone-FGC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJzLk[3Olgh|ryP NUDrUoVMW0GQR1XS
IMR-5 MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnZNpJ{UUN3ME2yNU45PDl2IN88US=> MXPTRW5ITVJ?
KP-N-YS NWXZNlhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrJTWM2OD1{MT64O|Uh|ryP NWLiUIlVW0GQR1XS
Mo-T NUKxNFk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XG[2lEPTB;MkKuNlE5PSEQvF2= M3;3fHNCVkeHUh?=
NCI-H128 NVjHdWk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL1bmpKSzVyPUKzMlU5PTNizszN NEXpXZlUSU6JRWK=
RH-1 M{HvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnpeFdKSzVyPUKzMlc5PjZizszN M4jHdXNCVkeHUh?=
NCI-H2171 Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDKUWtsUUN3ME2yOE4zPDh3IN88US=> M33ORnNCVkeHUh?=
RPMI-8866 NHPLWFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\EeWlEPTB;Mk[uO|QzKM7:TR?= MULTRW5ITVJ?
SK-N-FI M1vQXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrCTWM2OD1{Nz6zPFEyKM7:TR?= M1WybnNCVkeHUh?=
LOXIMVI MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDRTWM2OD1{Nz64NFUyKM7:TR?= MnXVV2FPT0WU
P31-FUJ NH3kUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vqbWlEPTB;M{GuOVM4PCEQvF2= NFPC[IlUSU6JRWK=
KMS-12-PE NH7aTnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzGVXBUUUN3ME20PU42OzB{IN88US=> MUPTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
in solvent
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9 2003 Phase 2
NCT02833506 Withdrawn Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IIA Fallopian Tube Cancer|Stage IIA Ovarian Cancer|Stage IIB Fallopian Tube Cancer|Stage IIB Ovarian Cancer|Stage IIC Fallopian Tube Cancer|Stage IIC Ovarian Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer Roswell Park Cancer Institute|National Cancer Institute (NCI) December 8 2017 Phase 1
NCT01869114 Recruiting Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|de Novo Myelodysplastic Syndromes|Myelodysplastic Syndrome With Isolated Del(5q)|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University July 8 2013 Phase 2
NCT01363752 Completed Kidney Transplantation Astellas Pharma Inc March 8 2011 Phase 4
NCT01010126 Completed Adult Hepatocellular Carcinoma|Advanced Adult Hepatocellular Carcinoma|Endometrial Serous Adenocarcinoma|Localized Non-Resectable Adult Liver Carcinoma|Lung Carcinoid Tumor|Malignant Pancreatic Gastrinoma|Malignant Pancreatic Glucagonoma|Malignant Pancreatic Insulinoma|Malignant Pancreatic Somatostatinoma|Metastatic Digestive System Neuroendocrine Tumor G1|Ovarian Carcinosarcoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Surface Papillary Adenocarcinoma|Pancreatic Alpha Cell Adenoma|Pancreatic Beta Cell Adenoma|Pancreatic Delta Cell Adenoma|Pancreatic G-Cell Adenoma|Pancreatic Polypeptide Tumor|Recurrent Adult Liver Carcinoma|Recurrent Digestive System Neuroendocrine Tumor G1|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Neuroendocrine Carcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Uterine Corpus Carcinoma|Regional Digestive System Neuroendocrine Tumor G1|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIA Uterine Corpus Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIB Uterine Corpus Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IIIC Uterine Corpus Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer|Stage IVA Uterine Corpus Cancer|Stage IVB Uterine Corpus Cancer|Uterine Carcinosarcoma National Cancer Institute (NCI) September 8 2009 Phase 2
NCT00703625 Completed Resistant Solid Malignancies Washington University School of Medicine March 8 2008 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID